Research programme: cannabinoid receptor CB1 antagonists - ACADIA Pharmaceuticals

Drug Profile

Research programme: cannabinoid receptor CB1 antagonists - ACADIA Pharmaceuticals

Latest Information Update: 30 Mar 2012

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders; Drug abuse; Obesity

Most Recent Events

  • 31 Dec 2010 Discontinued - Preclinical for Obesity in USA (PO)
  • 31 Dec 2010 Discontinued - Preclinical for Drug abuse in USA (PO)
  • 31 Dec 2010 Discontinued - Preclinical for Cognition disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top